SSII Stock: Aiming for $2.50 with +34% Upside from Current Levels

Key Takeaways

• The central reference point is $2.50, roughly 34% above the most recent closing price near $1.87 — a fallback target grounded in technical levels, not a formal analyst consensus.
• SS Innovations International, Inc. (SSII) has only one published analyst price target, $7.00 from Lucid Capital Markets, which implies a roughly 274% move and does not amount to a meaningful multi-analyst consensus.
• The strongest supporting factors are rapid revenue growth, rising procedure volumes and progress toward U.S. Food and Drug Administration (FDA) clearance.
• The biggest risks are persistent net losses, financing and dilution, regulatory timing, competition and heavy reliance on India.
• For more detail on this company, review its Major News and Today's Price Move, along with its Forecast and Earnings pages.
• For automated trading ideas, explore Trending AI Robots.

Analyst Price Targets and Consensus View

SS Innovations International, Inc. (SSII) operates as a commercial-stage surgical-robotics company, yet sell-side coverage remains thin. Only one published analyst price target stands out: a $7.00 objective from Lucid Capital Markets analyst Alex Nowak, issued with a Buy rating when coverage began in June 2026. Zacks Investment Research started coverage with a Neutral recommendation in October 2026 but offered no specific target in the materials available.

A single target does not form a true consensus, and the $7.00 level points to a move of roughly 274% from the current price — well beyond a realistic near-term goal. This article therefore treats $2.50 as a fallback level derived from the stock’s technical context and recent trading range, a zone the shares approached in early November 2026. It serves as a discussion point rather than a published forecast.

Current Market Position and Path Toward the Target

SSII closed near $1.87 on November 9, 2026, for a market capitalization of roughly $375 million. Reaching $2.50 would require an advance of about 34%, a sizable move. The 52-week range of $1.61 to $7.13 shows how far the shares have retreated from their peak and how volatile the stock continues to be.

The most plausible route to $2.50 runs through ongoing revenue growth and clear regulatory progress. First-half 2026 revenue came in at about $25 million, up roughly 66% year over year, while management targets completion of the FDA 510(k) review for its SSi Mantra system in the first quarter of 2027. Each milestone that reduces uncertainty around U.S. commercialization could support a re-rating, though sentiment still drives the shares as much as fundamentals do. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Support a Move Toward the Target

• Rapid revenue growth. Trailing-twelve-month revenue reached about $52.4 million, with strong year-over-year expansion.
• Installed-base momentum. Cumulative SSi Mantra installations reached 238 systems as of early September 2026, up 42% from year-end 2025, with procedure volumes rising 79% to 14,103.
• Telesurgery traction. More than 200 remote procedures, including cardiac cases, highlight a differentiated capability.
• FDA pathway. A response to the agency's request for additional information was submitted in October 2026, with review completion targeted for early 2027.
• Affordable positioning. The company markets a lower-cost alternative to established systems such as those from Intuitive Surgical (ISRG), which could appeal to price-sensitive providers.

What Could Prevent the Target From Being Reached

• Persistent losses. The company posted a net loss of about $12.4 million over the trailing twelve months and $6.2 million in the first half of 2026.
• Margin pressure. Gross margin narrowed to about 50.9% in the second quarter from 59.1% a year earlier.
• Financing and dilution. A $20 million secured convertible note issued in October 2026 adds leverage and potential shareholder dilution.
• Regulatory and execution risk. FDA timing remains subject to review, and competition from larger robotic-surgery players is substantial.
• Concentration. Revenue remains heavily dependent on India, and the stock's price-to-sales multiple stays elevated relative to peers despite the decline.

Technical Levels and Market Structure

The stock trades near the low end of its 52-week range, with the $1.61 low serving as a key support level. On the upside, the recent early-November trading zone around $2.11 to $2.45 forms a near-term resistance level, and the $2.50 central target sits just above that band. The $7.13 52-week high remains far above current levels and functions as a distant ceiling rather than an active reference point.

Time Horizon and What Investors Should Monitor

Published analyst targets typically reflect a roughly 12-month research horizon, though with only one covering analyst here, little can be inferred about timing. Investors should watch the FDA 510(k) decision window in the first quarter of 2027, the next quarterly earnings report and guidance, any additional analyst initiations or revisions, and further financing activity, all of which could shift the outlook materially.

Using AI Daily Buy/Sell Signals in My Process

In my own analysis, I often turn to Tickeron’s AI Daily Buy/Sell Signals to complement fundamental work. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and data-driven insights. It helps me spot new opportunities, track existing positions, and notice trend changes more efficiently than manual methods alone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume